286 related articles for article (PubMed ID: 29582559)
1. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
[TBL] [Abstract][Full Text] [Related]
2. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
Tiede A; Brand B; Fischer R; Kavakli K; Lentz SR; Matsushita T; Rea C; Knobe K; Viuff D
J Thromb Haemost; 2013 Apr; 11(4):670-8. PubMed ID: 23398640
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).
Klamroth R; Feistritzer C; Friedrich U; Lentz SR; Reichwald K; Zak M; Chowdary P
J Thromb Haemost; 2020 Feb; 18(2):341-351. PubMed ID: 31618804
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
[TBL] [Abstract][Full Text] [Related]
5. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.
Stennicke HR; Kjalke M; Karpf DM; Balling KW; Johansen PB; Elm T; Øvlisen K; Möller F; Holmberg HL; Gudme CN; Persson E; Hilden I; Pelzer H; Rahbek-Nielsen H; Jespersgaard C; Bogsnes A; Pedersen AA; Kristensen AK; Peschke B; Kappers W; Rode F; Thim L; Tranholm M; Ezban M; Olsen EH; Bjørn SE
Blood; 2013 Mar; 121(11):2108-16. PubMed ID: 23335368
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
[TBL] [Abstract][Full Text] [Related]
7. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C
Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
[TBL] [Abstract][Full Text] [Related]
8. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
Curry N; Albayrak C; Escobar M; Andre Holme P; Kearney S; Klamroth R; Misgav M; Négrier C; Wheeler A; Santagostino E; Shima M; Landorph A; Tønder SM; Lentz SR
Haemophilia; 2019 May; 25(3):373-381. PubMed ID: 30817066
[TBL] [Abstract][Full Text] [Related]
9. Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model.
Pastoft AE; Ezban M; Tranholm M; Lykkesfeldt J; Lauritzen B
Haemophilia; 2013 Nov; 19(6):913-9. PubMed ID: 23730746
[TBL] [Abstract][Full Text] [Related]
10. Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.
Chowdary P; Carcao M; Holme PA; Jiménez-Yuste V; Lentz SR; Møss J; Poulsen LH; Shen C; Tosetto A; Wheeler A; Santagostino E
Res Pract Thromb Haemost; 2019 Jul; 3(3):542-554. PubMed ID: 31294338
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
Agersø H; Stennicke HR; Pelzer H; Olsen EN; Merricks EP; Defriess NA; Nichols TC; Ezban M
Haemophilia; 2012 Nov; 18(6):941-7. PubMed ID: 22812621
[TBL] [Abstract][Full Text] [Related]
12. Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates.
Lunghi B; Bernardi F; Martinelli N; Frusconi S; Branchini A; Linari S; Marchetti G; Castaman G; Morfini M
J Thromb Haemost; 2019 Aug; 17(8):1288-1296. PubMed ID: 31055871
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
[TBL] [Abstract][Full Text] [Related]
16. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
Vargas Christensen I; Loftager M; Rode F; Mørck Nielsen H; Kreilgaard M; Larsen MS
J Thromb Haemost; 2019 Jun; 17(6):964-974. PubMed ID: 30924607
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII with a 237 amino acid B-domain has an extended half-life in F8-knockout mice.
Bloem E; Karpf DM; Nørby PL; Johansen PB; Loftager M; Rahbek-Nielsen H; Petersen HH; Blouse GE; Thim L; Kjalke M; Bolt G
J Thromb Haemost; 2019 Feb; 17(2):350-360. PubMed ID: 30525289
[TBL] [Abstract][Full Text] [Related]
20. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
